| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue, net | 16,427 | 18,839 | 23,033 | 18,464 |
| Cost of product sales | 1,202 | 836 | 2,061 | 851 |
| Research and development | 26,803 | 30,090 | 28,928 | 32,502 |
| Selling and marketing | 10,688 | 10,147 | 10,553 | 10,673 |
| General and administrative | 8,326 | 8,822 | 9,955 | 10,002 |
| Restructuring and impairment expenses | 377 | 13,091 | - | - |
| Total operating expense | 47,396 | 62,986 | 51,497 | 54,028 |
| Loss from operations | -30,969 | -44,147 | -28,464 | -35,564 |
| Interest expense | - | - | 12,230 | 13,117 |
| Interest income | 2,470 | 1,934 | 2,054 | 3,438 |
| Deferred royalty obligation interest expense | 8,996 | - | - | - |
| Effective interest expense on senior secured term loan facility-Loan Agreement | 4,396 | - | - | - |
| Interest expense | 13,392 | 12,997 | - | - |
| Other, net | 925 | -182 | 203 | 1,624 |
| Total other expense, net | -9,997 | -11,245 | -9,973 | -8,055 |
| Loss before income taxes | -40,966 | -55,392 | -38,437 | -43,619 |
| Income tax expense | 0 | 1,254 | 165 | 90 |
| Loss before equity in net losses of joint venture | -40,966 | -56,646 | -38,602 | -43,709 |
| Equity in net losses of joint venture | 0 | 0 | - | -260 |
| Net loss | -40,966 | -56,646 | -38,602 | -43,969 |
| Net loss per share, basic (in dollars per share) | -0.3 | -0.5 | -0.36 | -0.42 |
| Net loss per share, diluted (in dollars per share) | -0.3 | -0.5 | -0.36 | -0.42 |
| Weighted average shares outstanding, basic (in shares) | 136,446,534 | 113,743,358 | 107,202,374 | 104,824,877 |
| Weighted average shares outstanding, diluted (in shares) | 136,446,534 | 113,743,358 | 107,202,374 | 104,824,877 |
ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT)